1
Return

Early binding of anti-amyloid antibodies to CAA drives complement activation, inflammation and ARIA in mice

delete2026-06-26
delete0
delete
OA
AI
P
Praveen Bathini *
S
Stephan Schilling
J
Jens-Ulrich Rahfeld
D
David M. Holtzman
C
Cynthia A. Lemere
DOI:10.1186/s13024-026-00965-xdelete
deleteOriginal
deleteShare
deleteSave
View PDF
Abstract

Abstract

En 中文
Anti-amyloid antibody treatment for Alzheimer’s disease is linked to Amyloid-Related Imaging Abnormalities (ARIA), including vasogenic edema (ARIA-E) and microhemorrhages (ARIA-H), especially in ApoE ε4/4 carriers. To investigate mechanisms underlying ARIA, we examined the binding and temporal vascular effects of immunization with 3D6, the precursor to the anti-amyloid antibody bapineuzumab, in two aged Alzheimer’s disease amyloid mouse models. Acutely, 3D6 bound to cerebral amyloid angiopathy (CAA), resulting in C1q binding and classical complement activation. Weekly short-term immunization over 7 weeks resulted in elevated CAA- and plaque-associated complement deposition, red blood cell extravasation and microhemorrhages, and was accompanied by significant transcriptomic changes in genes related to complement, inflammation, vascular dysfunction, and endothelial lipid responses. Longer-term dosing over 13–15 weeks further increased complement deposition and was associated with blood-brain barrier disruption, MMP-9 upregulation, and microhemorrhages, accompanied by reduced amyloid burden and modest CAA clearance. C3 levels correlated with microhemorrhage severity. Perivascular macrophages co-localized with complement-decorated CAA in 3D6-treated mice. These findings implicate complement activation as an early key driver of ARIA and suggest that therapeutic targeting of complement may reduce ARIA risk.
Keywords:
Alzheimer's disease
Cerebral amyloid angiopathy
Anti-amyloid immunotherapy
Complement activation
ARIA
Blood-brain barrier
AI Summary

AI Summary

Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.

Journal

Molecular Neurodegeneration cover
Molecular Neurodegeneration
IF:
17.5
Papers:
1.4K
Citations:
1.1W

Organization

K
knight alzheimer's disease research center
Scholars:
5
Papers: 2
Citations: 0
F
Fraunhofer Institute for Cell Therapy and Immunology
Scholars:
93
Papers: 32
Citations: 850
R
riken
Scholars:
2.2W
Papers: 1.8W
Citations: 24
B
Brigham and Women's Hospital
Scholars:
2.3K
Papers: 1.2K
Citations: 9.0W
Cited Papers

Cited Papers

Citing Papers

Citing Papers